Actelion Stock Price, News & Analysis (OTCMKTS:ALIOF)

$278.50 0.00 (0.00 %)
(As of 11/17/2017 12:32 PM ET)
Previous Close$278.50
Today's Range$278.50 - $278.50
52-Week Range$138.01 - $286.30
VolumeN/A
Average Volume20 shs
Market Capitalization$29.89 billion
P/E Ratio35.21
Dividend YieldN/A
Beta1.5

About Actelion (OTCMKTS:ALIOF)

Actelion logoActelion Ltd. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of low molecular weight drugs. It specializes in the field of pulmonary arterial hypertension (PAH). It also specializes in human biology, especially in specific families of molecular targets, such as G-Protein Coupled Receptors. Its portfolio of PAH treatments covers the spectrum of disease, from World Health Organization (WHO) Functional Class (FC) II through to Functional Class (FC) IV, with oral, inhaled and intravenous medications. It also has treatments for a range of specialist diseases, including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides type cutaneous T-cell lymphoma. Its products include Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Ventavis (iloprost), Veletri (epoprostenol for injection), Zavesca (miglustat) and Valchlor (mechlorethamine) gel.


Industry, Sector and Symbol:
  • Industry: N/A
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: OTCMKTS:ALIOF
  • CUSIP: N/A
  • Web: www.actelion.com
Debt:
  • Current Ratio: 2.76%
  • Quick Ratio: 2.51%
Price-To-Earnings:
  • Trailing P/E Ratio: 35.21
Sales & Book Value:
  • Annual Sales: $2.45529 billion
  • Price / Sales: 12.17
  • Cash Flow: $9.13 per share
  • Price / Cash: 30.49
  • Book Value: $12.45 per share
  • Price / Book: 22.37
Profitability:
  • Net Income: $707.04 million
  • Net Margins: 28.95%
  • Return on Equity: 58.63%
  • Return on Assets: 38.83%
Misc:
  • Employees: 2,624
  • Outstanding Shares: 107,330,000
 

Frequently Asked Questions for Actelion (OTCMKTS:ALIOF)

What is Actelion's stock symbol?

Actelion trades on the OTCMKTS under the ticker symbol "ALIOF."

How were Actelion's earnings last quarter?

Actelion Ltd. (OTCMKTS:ALIOF) posted its quarterly earnings results on Monday, February, 16th. The company reported $0.87 EPS for the quarter, missing the Zacks' consensus estimate of $1.09 by $0.22. The firm had revenue of $501.50 million for the quarter, compared to analysts' expectations of $546.30 million. Actelion had a net margin of 28.95% and a return on equity of 58.63%. View Actelion's Earnings History.

When will Actelion make its next earnings announcement?

Actelion is scheduled to release their next quarterly earnings announcement on Thursday, November, 23rd 2017. View Earnings Estimates for Actelion.

Who are some of Actelion's key competitors?

Who are Actelion's key executives?

Actelion's management team includes the folowing people:

  • Jean-Pierre Garnier Ph.D., Chairman of the Board of Directors (Age 69)
  • Jean-Paul Clozel, Chief Executive Officer, Member of the Executive Committee, Delegate of the Board of Directors (Age 62)
  • Thomas Widman, Co-Founder
  • Andre C. Muller, Chief Financial Officer, Executive Vice President, Member of the Executive Committee (Age 53)
  • Otto Schwarz, Chief Operating Officer, Executive Vice President, Member of the Executive Committee (Age 61)
  • Guy Braunstein, Executive Vice President, Head of Global Clinical Development, Member of the Executive Committee (Age 60)
  • Nicholas Franco, Executive Vice President, Chief Business Development Officer, Member of the Executive Committee (Age 54)
  • Martine Clozel, Senior Vice President, Chief Scientific Officer, Head of Drug Discovery, Pharmacology & Preclinical Development, Member of the Extended Actelion Executive Committee (Age 61)
  • Marian Borovsky, Senior Vice President, Group General Counsel, Member of the Extended Actelion Executive Committee, Corporate Secretary to the Board of Directors (Age 47)
  • Christian Albrich, Senior Vice President, Head Global Human Resources, Member of the Extended Actelion Executive Committee (Age 52)

How do I buy Actelion stock?

Shares of Actelion can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Actelion's stock price today?

One share of Actelion stock can currently be purchased for approximately $278.50.

How big of a company is Actelion?

Actelion has a market capitalization of $29.89 billion and generates $2.45529 billion in revenue each year. Actelion employs 2,624 workers across the globe.

How can I contact Actelion?

Actelion's mailing address is Gewerbestrasse 16, ALLSCHWIL, 4123, Switzerland. The company can be reached via phone at +41-61-5656565 or via email at [email protected]


MarketBeat Community Rating for Actelion (OTCMKTS ALIOF)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Actelion and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Actelion (OTCMKTS:ALIOF)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Actelion (OTCMKTS:ALIOF)

Price Target History for Actelion (OTCMKTS:ALIOF)

Analysts' Ratings History for Actelion (OTCMKTS:ALIOF)

Show:
DateFirmActionRatingPrice TargetDetails
3/8/2017J P Morgan Chase & CoUpgradeNeutral -> OverweightView Rating Details
1/5/2017Jefferies Group LLCDowngradeBuy -> HoldView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Actelion (OTCMKTS:ALIOF)

Earnings by Quarter for Actelion (OTCMKTS:ALIOF)

Earnings History by Quarter for Actelion (OTCMKTS ALIOF)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/23/2017        
10/20/2016Q3 2016$2.12$2.39$603.47 million$626.61 millionViewN/AView Earnings Details
10/20/2015Q3 2015$1.61$1.90$527.94 million$533.07 millionViewN/AView Earnings Details
4/21/2015Q1 2015$1.28$1.68$506.91 million$539.65 millionViewN/AView Earnings Details
2/16/2015Q4 2014$1.09$0.87$546.30 million$501.50 millionViewN/AView Earnings Details
10/21/2014Q3 2014$1.50$1.61$511.25 million$525.03 millionViewN/AView Earnings Details
7/22/2014Q2 2014$1.37$2.00$516.67 million$583.43 millionViewN/AView Earnings Details
4/17/2014Q1 2014$1.12$1.65$504.04 million$531.17 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Actelion (OTCMKTS:ALIOF)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Actelion (OTCMKTS:ALIOF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Actelion (OTCMKTS ALIOF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Actelion (OTCMKTS:ALIOF)

Latest Headlines for Actelion (OTCMKTS ALIOF)

Source:
DateHeadline
Actelion Ltd. breached its 50 day moving average in a Bullish Manner : ALIOF-US : October 25, 2017Actelion Ltd. breached its 50 day moving average in a Bullish Manner : ALIOF-US : October 25, 2017
finance.yahoo.com - October 25 at 4:42 PM
What Factors Will Drive Johnson & Johnsons Q3 Earnings?What Factors Will Drive Johnson & Johnson's Q3 Earnings?
finance.yahoo.com - October 13 at 3:39 PM
Actelion Ltd. breached its 50 day moving average in a Bullish Manner : ALIOF-US : October 11, 2017Actelion Ltd. breached its 50 day moving average in a Bullish Manner : ALIOF-US : October 11, 2017
finance.yahoo.com - October 11 at 5:18 PM
Actelion Ltd. breached its 50 day moving average in a Bullish Manner : ALIOF-US : September 19, 2017Actelion Ltd. breached its 50 day moving average in a Bullish Manner : ALIOF-US : September 19, 2017
finance.yahoo.com - September 19 at 3:43 PM
Actelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : August 28, 2017Actelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : August 28, 2017
finance.yahoo.com - August 28 at 3:52 PM
Actelion Ltd. – Value Analysis (US OTC:ALIOF) : August 24, 2017Actelion Ltd. – Value Analysis (US OTC:ALIOF) : August 24, 2017
finance.yahoo.com - August 24 at 8:47 PM
Actelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : August 14, 2017Actelion Ltd. breached its 50 day moving average in a Bearish Manner : ALIOF-US : August 14, 2017
finance.yahoo.com - August 14 at 4:06 PM
ETFs with exposure to Actelion Ltd. : July 13, 2017ETFs with exposure to Actelion Ltd. : July 13, 2017
finance.yahoo.com - July 13 at 4:30 PM
Janssen Holding Acquires 92.51% Of ActelionJanssen Holding Acquires 92.51% Of Actelion
www.nasdaq.com - April 25 at 3:26 PM
Johnson & Johnson Announces Interim Result For Actelion Tender OfferJohnson & Johnson Announces Interim Result For Actelion Tender Offer
www.nasdaq.com - March 31 at 1:54 AM
Actelion FY16 Profit RisesActelion FY16 Profit Rises
www.rttnews.com - February 14 at 1:56 AM
Just 2 of the 13 Largest Drugmakers Have More Cash Than Debt -- Can You Guess Who They Are?Just 2 of the 13 Largest Drugmakers Have More Cash Than Debt -- Can You Guess Who They Are?
www.fool.com - February 8 at 3:37 PM
Johnson & Johnson May Never Recoup Its Costs to Buy ActelionJohnson & Johnson May Never Recoup Its Costs to Buy Actelion
www.fool.com - February 4 at 1:41 AM
Johnson & Johnson To Buy Actelion For $30 Bln With Spin-out Of New R&D CompanyJohnson & Johnson To Buy Actelion For $30 Bln With Spin-out Of New R&D Company
www.nasdaq.com - January 26 at 8:45 PM
Actelion Stock Up On $30 Bln Takeover Deal With JNJ; To Spin-Out R&D To New FirmActelion Stock Up On $30 Bln Takeover Deal With JNJ; To Spin-Out R&D To New Firm
www.rttnews.com - January 26 at 8:45 PM
[$$] J&J/Actelion: high pressure sale[$$] J&J/Actelion: high pressure sale
us.rd.yahoo.com - January 26 at 3:43 PM
[$$] Johnson & Johnson to buy Swiss biotech company Actelion for $30bn[$$] Johnson & Johnson to buy Swiss biotech company Actelion for $30bn
www.ft.com - January 26 at 3:43 PM
[$$] J&J digs deep to claim its $30bn Actelion prize[$$] J&J digs deep to claim its $30bn Actelion prize
www.ft.com - January 26 at 3:43 PM
Johnson & Johnson (JNJ) Stock Could Win BIG After Actelion PurchaseJohnson & Johnson (JNJ) Stock Could Win BIG After Actelion Purchase
investorplace.com - January 26 at 12:15 PM
Actelion Founders $1.5 Billion Payday Gives Him Shot at More - BloombergActelion Founder's $1.5 Billion Payday Gives Him Shot at More - Bloomberg
www.bloomberg.com - January 26 at 12:11 PM
Europe Markets: European stocks hang at 1-year high, buoyed by Actelion and bank shares Europe Markets: European stocks hang at 1-year high, buoyed by Actelion and bank shares
www.marketwatch.com - January 26 at 6:05 AM
J&J Seals $30 Billion Actelion Deal to Enter Rare Disease Arena - BloombergJ&J Seals $30 Billion Actelion Deal to Enter Rare Disease Arena - Bloomberg
www.bloomberg.com - January 26 at 4:39 AM
[$$] Novartis: buying time[$$] Novartis: buying time
www.ft.com - January 25 at 3:32 PM
Johnson & Johnson CEO Talks Trump, Taxes and M&A After Mixed EarningsJohnson & Johnson CEO Talks Trump, Taxes and M&A After Mixed Earnings
us.rd.yahoo.com - January 24 at 8:49 PM
[$$] J&J disappoints on 2017 forecasts due to strong dollar[$$] J&J disappoints on 2017 forecasts due to strong dollar
www.ft.com - January 24 at 3:48 PM
Johnson & Johnson CEO Talks Trump, M&A After Mixed EarningsJohnson & Johnson CEO Talks Trump, M&A After Mixed Earnings
www.thestreet.com - January 24 at 3:48 PM
VIVUS Licenses Rights to PAH Drugs from Selten PharmaVIVUS Licenses Rights to PAH Drugs from Selten Pharma
www.zacks.com - January 11 at 3:45 PM
[$$] Actelion/J&J: hypertension tactics[$$] Actelion/J&J: hypertension tactics
www.ft.com - December 22 at 3:26 PM
Wall Streets M&A Chatter From December 21Wall Street's M&A Chatter From December 21
feeds.benzinga.com - December 22 at 7:27 AM
[$$] Johnson & Johnson and Actelion disclose exclusive deal talks[$$] Johnson & Johnson and Actelion disclose 'exclusive' deal talks
www.ft.com - December 21 at 4:28 PM
European Stocks Drift Lower; Dollar Dominates Global Financial MarketsEuropean Stocks Drift Lower; Dollar Dominates Global Financial Markets
us.rd.yahoo.com - December 16 at 3:33 PM
5 Things You Must Know Before the Market Opens Friday5 Things You Must Know Before the Market Opens Friday
us.rd.yahoo.com - December 16 at 3:33 PM
Actelion receives positive CHMP opinion for chlormethine gel (Ledaga) for the treatment of MF-CTCLActelion receives positive CHMP opinion for chlormethine gel (Ledaga) for the treatment of MF-CTCL
us.rd.yahoo.com - December 16 at 3:33 PM
Johnson & Johnson Looks for New Deal Thats Just RightJohnson & Johnson Looks for New Deal That's Just Right
us.rd.yahoo.com - December 15 at 3:52 PM
Actelions Independent Streak Gives Rise to Doubt That Sanofi Will Fill the BreachActelion's Independent Streak Gives Rise to Doubt That Sanofi Will Fill the Breach
us.rd.yahoo.com - December 14 at 8:43 PM
[$$] Actelion: PAH, humbug[$$] Actelion: PAH, humbug
us.rd.yahoo.com - December 14 at 8:43 PM
J&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?J&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?
www.nasdaq.com - December 14 at 3:39 PM
[$$] Sanofi in talks to acquire biotech Actelion as J&J bows out[$$] Sanofi in talks to acquire biotech Actelion as J&J bows out
www.ft.com - December 14 at 1:31 AM
Actelion Is a Perfect Fit for Sanofi, but Probably Too Expensive: Exane BNPActelion Is a Perfect Fit for Sanofi, but Probably Too Expensive: Exane BNP
www.thestreet.com - December 7 at 4:06 PM
Johnson & Johnson Throws Caution to the Wind With a Large Bid for ActelionJohnson & Johnson Throws Caution to the Wind With a Large Bid for Actelion
www.fool.com - November 30 at 12:41 PM
Actelion Ltd. breached its 50 day moving average in a Bullish Manner : ALIOF-US : November 28, 2016Actelion Ltd. breached its 50 day moving average in a Bullish Manner : ALIOF-US : November 28, 2016
us.rd.yahoo.com - November 29 at 1:25 PM
J&J (JNJ) Confirms it Approached Actelion for Possible DealJ&J (JNJ) Confirms it Approached Actelion for Possible Deal
us.rd.yahoo.com - November 29 at 1:25 PM
Stock Market News for November 28, 2016Stock Market News for November 28, 2016
us.rd.yahoo.com - November 29 at 1:25 PM
[$$] Actelion: independent thinking[$$] Actelion: independent thinking
www.ft.com - November 29 at 1:25 PM
[$$] Actelion weighs complicated deal to combine with part of J&J[$$] Actelion weighs complicated deal to combine with part of J&J
www.ft.com - November 29 at 1:25 PM
Dow, S&P 500 Set for Record Closes in Light Black Friday SessionDow, S&P 500 Set for Record Closes in Light Black Friday Session
www.thestreet.com - November 25 at 3:22 PM

Social Media

Financials

Financials are not available for this stock.

Chart

Actelion (OTCMKTS ALIOF) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.